ISI Group Initiates Coverage of LabCorp, Quest at Neutral | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm International Strategy & Investment Group today initiated coverage of clinical laboratories Laboratory Corporation of America and Quest Diagnostics with Neutral ratings on their stock.

ISI put a price target of $110.50 on LabCorp shares and a price target of $63.00 on Quest's stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.